About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Six-Month Data Shows Visceral Fat Reduction And Lean Mass StabilityAt the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizing lean mass with a 2% increase.The results suggest that WVE-007 could lead to greater improvements in body composition compared to existing treatments, with the company expecting to initiate the Phase 2a multidose portion of INLIGHT in individu ...

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences’ executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Wave Life Sciences securities?If you purchased Wave Life Sciences securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. ...

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints | Reuters But results from a 400 mg dose after three months showed only about a 5% reduction in visceral fat. "Investors are likely discouraged by the 400 mg data at 3 months, which look similar on visceral fat as 240 mg and not as good on total fat and lean mass, though there appear to be some differences in the baseline BMI and body composition of this cohort that could explain some of these observations," said a Leerink Pa ...

Wave Life Sciences (NasdaqGM:WVE) Update / briefing March 26, 2026 08:30 AM ET Company ParticipantsCheng Li - Director of Biotech Equity ResearchChristopher Wright - CMOErik Ingelsson - CSOKate Roush - VP of Investor Relations and Corporate AffairsMichael King - Rodman & RenshawPaul Bolno - President and CEOSteve Seedhouse - Biotechnology Equity ResearchConference Call ParticipantsAnanda Ghosh - Vice President and Research Analyst of Equity Research BiotechBill Maughan - Managing Director and Equity Researc ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass (+2%), and reductions in waist circumference (-3%) and body weight (-1%) WVE-007 led to greater improvement in body composition (visceral fat-to-muscle ratio) at six months versus that seen with weekly GLP-1 in later-stage trial (BMI: ~37 kg/m2), even with participants in Phase 1 portion of INLIGHT ...

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund”. A copy of the letter is available to download here. The small caps' earnings are reaccelerating in 2025, as the firm forecasted a year ago. The market also experienced a low-quality rally within the small-cap space. Against this backdrop, the Small Cap Growth Fund underperformed the Russell 2000 Growth Index benchmark in the quarter, returning 0.51% vs. 1.22% for the benchmark. Head ...

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Core Viewpoint - Investors are increasingly concerned about the future of experimental drugs for hard-to-treat diseases due to recent rejections by the U.S. Food and Drug Administration (FDA) [1][4]. Group 1: FDA Rejections and Investor Sentiment - The FDA has denied or discouraged applications for at least eight drugs in the past year, including gene therapies for Huntington's disease and Hunter syndrome, as well as a drug for a blood condition [2]. - The FDA's rejections stem from issues with the evidence provided by companies, such as the lack of placebo-controlled studies and reliance on biomarkers instead of direct efficacy measurements [3]. - Companies have accused the FDA of reversing previous guidance, leading to investor wariness about the agency's unpredictability and its impact on future treatments [4]. Group 2: Regulatory Standards and Implications - Historically, the FDA was more lenient with drugs for rare diseases, allowing approvals based on less rigorous studies, which has drawn both support and criticism [5]. - The recent decisions have raised questions about whether the FDA's standards have changed for other drugs in development, as seen with UniQure being asked to conduct a new placebo-controlled study [6]. - Analysts are monitoring several companies, including Dyne Therapeutics and Taysha Gene Therapies, whose stock prices have declined this year amid regulatory uncertainty [8]. Group 3: Company Responses and Future Outlook - Dyne Therapeutics expressed confidence in its development strategy and ongoing dialogue with the FDA, while other companies like Taysha, Wave, and Lexeo declined to comment [9]. - Denali Therapeutics is awaiting a decision on its drug candidate for Hunter syndrome, with the FDA delaying its review by three months, now expected by April 5 [12]. - Some investors perceive a disconnect between the FDA's public commitments to flexibility and its recent decisions, leading to skepticism about the success of companies relying on flexible data acceptance [13]. Group 4: FDA's Position on Data Requirements - A senior FDA official stated that the agency's stance on using biomarkers for accelerated approval remains unchanged, and non-randomized data can still lead to full approval [15]. - The official emphasized that significant improvements in severely ill patients could warrant full regulatory approval even with limited data [16]. - The FDA requires randomized data primarily in cases where conditions are heterogeneous or when the potential for misleading results is high [17].

Core Insights - Wave Life Sciences announced the acceptance of a late-breaking oral presentation of data from its RestorAATion-2 clinical trial of WVE-006 at the ATS conference in May 2026, which will include data from both the 400 mg multidose cohort and the 600 mg single dose cohort [1][2] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, aiming to transform human health through its innovative RNA-targeting modalities [3] - The company's pipeline includes programs for alpha-1 antitrypsin deficiency (WVE-006), obesity (WVE-007), and PNPLA3 I148M liver disease (WVE-008), along with clinical programs in Duchenne muscular dystrophy and Huntington's disease [3] Clinical Trial Details - The RestorAATion-2 trial focuses on WVE-006, a GalNAc-conjugated RNA editing oligonucleotide targeting alpha-1 antitrypsin deficiency, a single-gene disorder that affects both lung and liver health [2] - The late-breaking oral presentation will be held on May 18, 2026, featuring Kenneth R. Chapman as the presenter [3]